Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice

• Main Authors: Hani Jouihan (Author), Sarah Will (Author), Silvia Guionaud (Author), Michelle L. Boland (Author), Stephanie Oldham (Author), Peter Ravn (Author), Anthony Celeste (Author), James L. Trevaskis (Author)
• Format: Book
• Published: Elsevier, 2017-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Nonalcoholic steatohepatitis (NASH) is an unmet need associated with metabolic syndrome. There are no approved therapies for NASH; however, glucagon-like peptide-1 receptor (GLP-1R) and farnesoid-X receptor (FXR) agonists are promising drug targets. We investigated the therapeutic effects...